These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30789540)

  • 41. The Association of Oxaliplatin-Containing Adjuvant Chemotherapy Duration with Overall and Cancer-Specific Mortality in Individuals with Stage III Colon Cancer: A Population-Based Retrospective Cohort Study.
    Sue-Chue-Lam C; Brezden-Masley C; Sutradhar R; Yu AYX; Baxter NN
    Curr Oncol; 2023 Jul; 30(7):6508-6532. PubMed ID: 37504338
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Geographic Variation in Oxaliplatin Chemotherapy and Survival in Patients With Colon Cancer.
    Panchal JM; Lairson DR; Chan W; Du XL
    Am J Ther; 2016; 23(3):e720-9. PubMed ID: 24368611
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Explaining black-white differences in receipt of recommended colon cancer treatment.
    Baldwin LM; Dobie SA; Billingsley K; Cai Y; Wright GE; Dominitz JA; Barlow W; Warren JL; Taplin SH
    J Natl Cancer Inst; 2005 Aug; 97(16):1211-20. PubMed ID: 16106026
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
    Wagner AD; Grothey A; Andre T; Dixon JG; Wolmark N; Haller DG; Allegra CJ; de Gramont A; VanCutsem E; Alberts SR; George TJ; O'Connell MJ; Twelves C; Taieb J; Saltz LB; Blanke CD; Francini E; Kerr R; Yothers G; Seitz JF; Marsoni S; Goldberg RM; Shi Q
    J Natl Cancer Inst; 2021 Apr; 113(4):400-407. PubMed ID: 32835356
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
    de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
    Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utilisation of Adjuvant Chemotherapy and 5-Year Survival Analysis of Prospectively Recorded Cohort Data for Older Adults Versus Younger Adults with Resected Primary Colon Cancer.
    Shafiei M; Beale P; Blinman P
    J Gastrointest Cancer; 2020 Sep; 51(3):988-997. PubMed ID: 31811472
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.
    Sundararajan V; Mitra N; Jacobson JS; Grann VR; Heitjan DF; Neugut AI
    Ann Intern Med; 2002 Mar; 136(5):349-57. PubMed ID: 11874307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer.
    Hu CY; Delclos GL; Chan W; Du XL
    Med Oncol; 2011 Dec; 28(4):1062-74. PubMed ID: 20714945
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer.
    Lairson DR; Parikh RC; Cormier JN; Chan W; Du XL
    Pharmacoeconomics; 2014 Oct; 32(10):1005-13. PubMed ID: 24920195
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
    Papadimitriou CA; Papakostas P; Karina M; Malettou L; Dimopoulos MA; Pentheroudakis G; Samantas E; Bamias A; Miliaras D; Basdanis G; Xiros N; Klouvas G; Bafaloukos D; Kafiri G; Papaspirou I; Pectasides D; Karanikiotis C; Economopoulos T; Efstratiou I; Korantzis I; Pisanidis N; Makatsoris T; Matsiakou F; Aravantinos G; Kalofonos HP; Fountzilas G
    BMC Med; 2011 Jan; 9():10. PubMed ID: 21281463
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.
    Salem ME; Yin J; Goldberg RM; Pederson LD; Wolmark N; Alberts SR; Taieb J; Marshall JL; Lonardi S; Yoshino T; Kerr RS; Yothers G; Grothey A; Andre T; De Gramont A; Shi Q
    Ann Oncol; 2020 Apr; 31(4):480-486. PubMed ID: 32085892
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer.
    Degirmencioglu S; Tanrıverdi O; Demiray AG; Senol H; Dogu GG; Yaren A
    J Int Med Res; 2019 Jun; 47(6):2507-2515. PubMed ID: 31099282
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer.
    Gross CP; McAvay GJ; Guo Z; Tinetti ME
    Cancer; 2007 Jun; 109(12):2410-9. PubMed ID: 17510973
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients.
    Lund JL; Stürmer T; Sanoff HK; Brookhart A; Sandler RS; Warren JL
    Cancer; 2013 Jun; 119(11):2038-47. PubMed ID: 23512326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Racial/ethnic disparities in the adjuvant chemotherapy of locally advanced colon cancer patients.
    Zhong X; Guo Z; Gao P; Song Y; Sun J; Chen X; Sun Y; Wang Z
    J Surg Res; 2018 Aug; 228():27-34. PubMed ID: 29907221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.
    Aspinall SL; Good CB; Zhao X; Cunningham FE; Heron BB; Geraci M; Passero V; Stone RA; Smith KJ; Rogers R; Shields J; Sartore M; Boyle DP; Giberti S; Szymanski J; Smith D; Ha A; Sessions J; Depcinski S; Fishco S; Molina I; Lepir T; Jean C; Cruz-Diaz L; Motta J; Calderon-Vargas R; Maland J; Keefe S; Tague M; Leone A; Glovack B; Kaplan B; Cosgriff S; Kaster L; Tonnu-Mihara I; Nguyen K; Carmichael J; Clifford L; Lu K; Chatta G
    BMC Cancer; 2015 Feb; 15():62. PubMed ID: 25884851
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer.
    Hu CY; Chan W; Delclos GP; Du XL
    Am J Clin Oncol; 2012 Jun; 35(3):228-36. PubMed ID: 21383605
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessing functional status and the survival benefit of chemotherapy for advanced non-small cell lung cancer using administrative claims data.
    Feliciano J; Gardner L; Hendrick F; Edelman MJ; Davidoff A
    Lung Cancer; 2015 Jan; 87(1):59-64. PubMed ID: 25443272
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C-SCANS study.
    Cespedes Feliciano EM; Lee VS; Prado CM; Meyerhardt JA; Alexeeff S; Kroenke CH; Xiao J; Castillo AL; Caan BJ
    Cancer; 2017 Dec; 123(24):4868-4877. PubMed ID: 28881381
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
    JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.